Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?

Table 1 Characteristics between neoadjuvant chemotherapy groups

	NACT (n = 79)	Surgery only (n = 162)	P value
Age (median, range)	62 (42-75)	69 (37-87)	< 0.0011
Sex
Male	67	135	0.770
Female	12	27
Barrett’s oesophagus	30 (38%)	73 (45.1%)	0.297
Tumour location
Upper	1 (1.3%)	4 (2.5%)	0.562
Mid	0 (0%)	3 (1.9%)	0.233
Lower	29 (38.7%)	65 (40.6%)	0.775
GOJ	45 (60%)	88 (55%)	0.471
Tumour differentiation
Poor	35 (46.1%)	76 (48.7%)	0.703
Mod	38 (50%)	67 (42.9%)	0.311
Well	3 (3.9%)	13 (8.3%)	0.216
Stage1
I	12 (15.6%)	43 (27.7%)	0.0401
II	20 (26%)	27 (17.4%)	0.127
III	43 (55.8%)	80 (51.6%)	0.543
IV	1 (1.3%)	5 (3.2%)	0.384
Nodes positive	1 (0-20)	1 (0-22)	0.344

¹American Joint Committee on Cancer (AJCC) 8^th edition. NACT: Neoadjuvant chemotherapy; GOJ: Gastro-oesophageal junction.